Daniel Lee Flynn is CSO at Deciphera Pharmaceuticals, Inc. (DCPH). They have made 13 open-market trades across 1 company since 2019, most recently 2023-06-16.
CIK 0001713712
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DCPH | 57,158 | $1.5M |
Shares reported on the most recent Form 4, priced at the 2023-06-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DCPH | SELL | 2023-06-16 | 2023-06-21 | $14.40 | $24K | -5.2% | -7.4% | -5.4% |
| DCPH | SELL | 2023-02-16 | 2023-02-17 | $15.10 | $21K | -0.3% | +6.5% | -4.8% |
| DCPH | SELL | 2023-01-17 | 2023-01-19 | $21.24 | $102K | -14.6% | -27.1% | -22.9% |
| DCPH | SELL | 2022-06-16 | 2022-06-21 | $10.75 | $19K | +9.9% | +12.0% | +54.2% |
| DCPH | SELL | 2022-02-16 | 2022-02-18 | $9.05 | $12K | -5.9% | +12.1% | +43.7% |
| DCPH | SELL | 2021-02-16 | 2021-02-18 | $48.87 | $25K | -2.4% | +0.2% | -27.5% |
| DCPH | SELL | 2019-12-12 | 2019-12-13 | $60.00 | $1.9M | +4.0% | -4.3% | -39.4% |
| DCPH | SELL | 2019-12-09 | 2019-12-11 | $55.00 | $8.4M | +16.8% | +7.1% | -14.4% |
| DCPH | SELL | 2019-11-11 | 2019-11-13 | $48.01 | $6.9M | -0.3% | +33.0% | +41.6% |
| DCPH | SELL | 2019-11-08 | 2019-11-13 | $48.01 | $14.2M | -0.3% | +33.0% | +41.6% |
| DCPH | SELL | 2019-10-28 | 2019-10-30 | $40.00 | $1.2M | +10.0% | +7.0% | +48.0% |
| DCPH | SELL | 2019-08-13 | 2019-08-13 | $40.74 | $11.0M | -0.7% | +0.4% | +33.7% |
| DCPH | SELL | 2019-01-16 | 2019-01-18 | $26.00 | $4.0M | +1.1% | +10.2% | -11.8% |
| DCPH | SELL · 10b5-1 | 2019-01-11 | 2019-01-15 | $26.00 | $8K | -0.6% | +9.9% | -10.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.